Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1,…
Eli Lilly to build $6 billion Alabama manufacturing plant
Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept.…
Higher PFAS levels reduce blood sugar improvements after teen bariatric surgery
A new USC study shows teens with higher blood levels of per- and polyfluoroalkyl substances (PFAS) measured before…
CDC panel debates hepatitis B vaccine for newborns at a contentious meeting
 Key Insights The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP)…
WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
Lilly cuts price for obesity drug Zepbound
Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…
Ozempic pill fails to slow Alzheimer’s disease
Ozempic warning: Experts warn of side effects from weight loss drug Experts are warning of the possible side…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is best?
In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The…
Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg |…
Ireland business chamber welcomes Chinese investment despite US, EU pressures
Chinese investment is still being actively welcomed in Ireland, the head of a major business organisation said, even…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…